HCAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Health Catalyst Inc (HCAT) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant headwinds, including bearish technical indicators, insider selling, downgraded analyst ratings, and weak financial performance. Additionally, there are no strong positive catalysts or proprietary trading signals to support a buy decision.
The technical indicators are bearish. The MACD histogram is negative and contracting, RSI indicates oversold conditions at 18.915, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 1.066 and S2 at 0.962.
NULL identified. While there is a focus on long-term execution improvements under new leadership, these efforts are unlikely to yield immediate results.
Insider selling has increased by 869.22% over the last month.
Analysts have downgraded the stock, citing revenue and margin pressures likely to persist into
Weak financial performance with declining revenue (-6.19% YoY) and negative EPS (-1.28).
No recent congress trading data or influential figure activity to suggest confidence in the stock.
In Q4 2025, revenue dropped by -6.19% YoY to $74.68 million. Net income improved to -$91.03 million (up 340.31% YoY), but the company remains unprofitable. EPS increased to -1.28 (up 287.88% YoY), and gross margin improved to 35.48% (up 15.42% YoY). However, these improvements are overshadowed by ongoing operational challenges and delayed FY26 guidance.
Analysts have downgraded the stock significantly. Wells Fargo downgraded the stock to Equal Weight with a price target of $1, citing persistent revenue and margin pressures. Other firms, including Stephens, Citi, and Stifel, have also lowered price targets, reflecting a lack of confidence in the company's near-term prospects.
